Meng-Heng Hsieh1, Yueh-Fu Fang1, Fu-Tsai Chung1, Chung-Shu Lee1, Yu-Chen Chang2, Yuan-Zhang Liu3, Cheng-Hsien Wu3, Horng-Chyuan Lin1. 1. Department of Thoracic Medicine, Chang Gung Medical Foundation, Chang Gung University, College of Medicine, Taoyuan, Taiwan. 2. Department of Nuclear Medicine, Chang Gung Medical Foundation, Chang Gung University, College of Medicine, Taoyuan, Taiwan. 3. Department of Radiology, Chang Gung Medical Foundation, Chang Gung University, College of Medicine, Taoyuan, Taiwan.
Abstract
BACKGROUND: Previous surveillance methods to monitor the prognoses of patients with bronchiectasis are too complex for use in daily practice. The 6-minute walk test (6MWT) is a simple exercise test to predict the prognosis of chronic obstructive airway disease and numerous chronic lung diseases, including idiopathic pulmonary fibrosis. No studies have investigated exercise-induced oxygen desaturation (EID) and distance-saturation product (DSP) of 6MWT to predict the prognoses of patients with bronchiectasis. METHODS: This was a prospective study to identify correlations between variables of 6MWT and mortality in patients with bronchiectasis over a 6-year period. The study cohort included 69 patients with stable non-cystic fibrosis (non-CF) bronchiectasis who were regularly evaluated for functional status via 6-minute walk distance (6MWD), spirometry, BODE index, EID, and DSP. RESULTS: Of the 69 patients, 9 (13%) died and 60 (87%) survived during the 6-year follow-up period. The percentage of EID was higher [7 of 9 patients (78%) vs. 22 of 60 patients (27%), P=0.003] in the non-survivors group. The 6MWD (467.9±77.1 vs. 363.7±126.7 m, P=0.001) was higher in the survivors group. DSP was significantly lower in the non-survivors group (411.0±78.4 vs. 283.9±90.0 m%, P<0.001). Multivariate analysis showed that DSP (OR =0.983; 95% CI: 0.974-0.993, P=0.001) was the best parameter of 6MWT to predict mortality. Patients with a lower DSP of <280 m% were at a 66.5-fold greater risk (OR =66.5; 95% CI: 9.4-469.2) of 6-year mortality compared with those with DSP >280 m% (P<0.001). CONCLUSIONS: DSP is a simple parameter to predict 6-year mortality in patients with non-CF bronchiectasis.
BACKGROUND: Previous surveillance methods to monitor the prognoses of patients with bronchiectasis are too complex for use in daily practice. The 6-minute walk test (6MWT) is a simple exercise test to predict the prognosis of chronic obstructive airway disease and numerous chronic lung diseases, including idiopathic pulmonary fibrosis. No studies have investigated exercise-induced oxygen desaturation (EID) and distance-saturation product (DSP) of 6MWT to predict the prognoses of patients with bronchiectasis. METHODS: This was a prospective study to identify correlations between variables of 6MWT and mortality in patients with bronchiectasis over a 6-year period. The study cohort included 69 patients with stable non-cystic fibrosis (non-CF) bronchiectasis who were regularly evaluated for functional status via 6-minute walk distance (6MWD), spirometry, BODE index, EID, and DSP. RESULTS: Of the 69 patients, 9 (13%) died and 60 (87%) survived during the 6-year follow-up period. The percentage of EID was higher [7 of 9 patients (78%) vs. 22 of 60 patients (27%), P=0.003] in the non-survivors group. The 6MWD (467.9±77.1 vs. 363.7±126.7 m, P=0.001) was higher in the survivors group. DSP was significantly lower in the non-survivors group (411.0±78.4 vs. 283.9±90.0 m%, P<0.001). Multivariate analysis showed that DSP (OR =0.983; 95% CI: 0.974-0.993, P=0.001) was the best parameter of 6MWT to predict mortality. Patients with a lower DSP of <280 m% were at a 66.5-fold greater risk (OR =66.5; 95% CI: 9.4-469.2) of 6-year mortality compared with those with DSP >280 m% (P<0.001). CONCLUSIONS: DSP is a simple parameter to predict 6-year mortality in patients with non-CF bronchiectasis.
Entities:
Keywords:
6-minute walk test (6MWT); Non-cystic fibrosis (non-CF) bronchiectasis; distance-saturation product (DSP); mortality
Authors: Gaik C Ooi; Pek L Khong; Moira Chan-Yeung; James C M Ho; Philip K S Chan; Jeriel C K Lee; Wah K Lam; Kenneth W T Tsang Journal: Radiology Date: 2002-12 Impact factor: 11.105
Authors: Christopher J Lettieri; Steven D Nathan; Robert F Browning; Scott D Barnett; Shahzad Ahmad; Andrew F Shorr Journal: Respir Med Date: 2006-03-20 Impact factor: 3.415
Authors: Miguel Á Martínez-García; Javier de Gracia; Monserrat Vendrell Relat; Rosa-Maria Girón; Luis Máiz Carro; David de la Rosa Carrillo; Casilda Olveira Journal: Eur Respir J Date: 2013-11-14 Impact factor: 16.671
Authors: Molly K Ball; Gregory B Waypa; Paul T Mungai; Jacqueline M Nielsen; Lyubov Czech; V Joseph Dudley; Lauren Beussink; Robert W Dettman; Sara K Berkelhamer; Robin H Steinhorn; Sanjiv J Shah; Paul T Schumacker Journal: Am J Respir Crit Care Med Date: 2014-02-01 Impact factor: 21.405
Authors: Esam H Alhamad; Shaffi Ahmad Shaik; Majdy M Idrees; Mohammed O Alanezi; Arthur C Isnani Journal: BMC Pulm Med Date: 2010-08-09 Impact factor: 3.317
Authors: Rebekah A Blakney; Emily E Ricotta; Dean Follmann; Jessica Drew; Kelly A Carey; Lisa N Glass; Chevalia Robinson; Sandra MacDonald; Pamela J McShane; Kenneth N Olivier; Kevin Fennelly; D Rebecca Prevots Journal: BMC Infect Dis Date: 2022-01-21 Impact factor: 3.090